Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6403036 | 0.90 | CACNA1H (0.37) | CACNA1HOPRM1OPRD1OPRK1ALOX5 | |
| SCHEMBL6407163 | 0.85 | CA1 (0.42) | ALOX5CA1 | |
| SCHEMBL6401745 | 0.78 | LMNA (0.45) | LMNACACNA1HOPRM1OPRD1OPRK1 | |
| SCHEMBL6401980 | 0.78 | LMNA (0.45) | LMNACACNA1HOPRM1OPRD1OPRK1 | |
| SCHEMBL6401370 | 0.76 | L3MBTL1 (0.40) | ALOX5 | |
| SCHEMBL6408723 | 0.76 | CA1 (0.41) | ALOX5CA1 | |
| SCHEMBL7790158 | 0.72 | CCR6 (0.42) | LMNAOPRM1OPRD1OPRK1BCHE | |
| SCHEMBL6409442 | 0.71 | SLC7A5 (0.39) | LMNABACE1CA1 | |
| SCHEMBL6181959 | 0.71 | CTSL (0.40) | LMNAOPRM1OPRD1OPRK1 | |
| SCHEMBL7799705 | 0.70 | CCR6 (0.38) | LMNAOPRM1OPRD1OPRK1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6900237-B2 | Sulfonamide compounds as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2005-05-31 | — | — | US | disclosed |
| US-20030158231-A1 | Sulfonamide compounds as protease inhibitors | Celera Corporation | 2003-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158231-A1 | Sulfonamide compounds as protease inhibitors | PRSS1, PRSS3, SPINT2 | LMNA 3804/4885CACNA1H 2723/4885OPRM1 3772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.